WO2003070252A1 - Agents antiprurigineux - Google Patents
Agents antiprurigineux Download PDFInfo
- Publication number
- WO2003070252A1 WO2003070252A1 PCT/JP2003/001920 JP0301920W WO03070252A1 WO 2003070252 A1 WO2003070252 A1 WO 2003070252A1 JP 0301920 W JP0301920 W JP 0301920W WO 03070252 A1 WO03070252 A1 WO 03070252A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prostaglandin
- drug
- prostaglandins
- symptoms
- group
- Prior art date
Links
- 230000001139 anti-pruritic effect Effects 0.000 title abstract description 16
- 239000003908 antipruritic agent Substances 0.000 title description 19
- 150000003180 prostaglandins Chemical class 0.000 claims abstract description 55
- 239000003814 drug Substances 0.000 claims abstract description 54
- 229940079593 drug Drugs 0.000 claims abstract description 47
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 206010003645 Atopy Diseases 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 230000001823 pruritic effect Effects 0.000 claims description 45
- 208000024891 symptom Diseases 0.000 claims description 33
- -1 RS93520 Chemical compound 0.000 claims description 22
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 21
- 201000008937 atopic dermatitis Diseases 0.000 claims description 21
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 19
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 19
- OJZYRQPMEIEQFC-UAWLTFRCSA-N limaprost Chemical compound CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O OJZYRQPMEIEQFC-UAWLTFRCSA-N 0.000 claims description 15
- 229950009365 limaprost Drugs 0.000 claims description 15
- 229960000711 alprostadil Drugs 0.000 claims description 13
- 229960002986 dinoprostone Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 229940044601 receptor agonist Drugs 0.000 claims description 13
- 239000000018 receptor agonist Substances 0.000 claims description 13
- 229960002890 beraprost Drugs 0.000 claims description 9
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 claims description 9
- 229960003400 sulprostone Drugs 0.000 claims description 9
- UQZVCDCIMBLVNR-TWYODKAFSA-N sulprostone Chemical compound O[C@@H]1CC(=O)[C@H](C\C=C/CCCC(=O)NS(=O)(=O)C)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 UQZVCDCIMBLVNR-TWYODKAFSA-N 0.000 claims description 9
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims description 8
- CTXLUMAOXBULOZ-QEQARHSSSA-N (z)-7-[(1r,2r,5s)-5-hydroxy-2-[(e,3s)-3-hydroxy-3-methyloct-1-enyl]-3-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC[C@](C)(O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O CTXLUMAOXBULOZ-QEQARHSSSA-N 0.000 claims description 8
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 108010088540 Prostaglandin E receptors Proteins 0.000 claims description 6
- ARUGKOZUKWAXDS-SEWALLKFSA-N cicaprost Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 claims description 6
- 229950000634 cicaprost Drugs 0.000 claims description 6
- 229950001524 clinprost Drugs 0.000 claims description 6
- 229960001123 epoprostenol Drugs 0.000 claims description 6
- 229960002240 iloprost Drugs 0.000 claims description 6
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- QIGRQPVOWVHYBT-KABTVRTISA-N methyl 5-[(3as,5r,6r,6as)-5-hydroxy-6-[(e,3s)-3-hydroxyoct-1-enyl]-1,3a,4,5,6,6a-hexahydropentalen-2-yl]pentanoate Chemical compound C1=C(CCCCC(=O)OC)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 QIGRQPVOWVHYBT-KABTVRTISA-N 0.000 claims description 6
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 claims description 6
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 claims description 6
- 108050000258 Prostaglandin D receptors Proteins 0.000 claims description 5
- 108050008032 Prostaglandin DP receptors Proteins 0.000 claims description 5
- 102000008866 Prostaglandin E receptors Human genes 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 claims description 5
- 229960005249 misoprostol Drugs 0.000 claims description 5
- 230000003287 optical effect Effects 0.000 claims description 5
- 239000002522 prostaglandin receptor stimulating agent Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- MXDQOCKVVLKVJS-QKIVIXBWSA-N (z)-7-[(1r,2r,3r)-3-methoxy-2-[(e,3s)-3-methoxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC[C@H](OC)\C=C\[C@H]1[C@H](OC)CC(=O)[C@@H]1C\C=C/CCCC(O)=O MXDQOCKVVLKVJS-QKIVIXBWSA-N 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 4
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- DPNOTBLPQOITGU-LDDQNKHRSA-N 11-deoxyprostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1CCC(=O)[C@@H]1CCCCCCC(O)=O DPNOTBLPQOITGU-LDDQNKHRSA-N 0.000 claims description 3
- WJDXRLOGFZXXNY-OFYJTPHNSA-N 5-[(3as,5r,6r,6as)-5-hydroxy-6-[(e,4s)-4-hydroxy-4-methyloct-1-enyl]-1,3a,4,5,6,6a-hexahydropentalen-2-yl]pentanoic acid Chemical compound C1=C(CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/C[C@@](C)(O)CCCC)[C@H](O)C[C@@H]21 WJDXRLOGFZXXNY-OFYJTPHNSA-N 0.000 claims description 3
- XMQKDOCUWFCMEJ-UHFFFAOYSA-N 7-[2-[4-(1-hydroxyhexyl)phenyl]-5-oxocyclopentyl]heptanoic acid Chemical compound C1=CC(C(O)CCCCC)=CC=C1C1C(CCCCCCC(O)=O)C(=O)CC1 XMQKDOCUWFCMEJ-UHFFFAOYSA-N 0.000 claims description 3
- 108050006400 Cyclin Proteins 0.000 claims description 3
- 102000016736 Cyclin Human genes 0.000 claims description 3
- DPNOTBLPQOITGU-UHFFFAOYSA-N Doproston B Natural products CCCCCC(O)C=CC1CCC(=O)C1CCCCCCC(O)=O DPNOTBLPQOITGU-UHFFFAOYSA-N 0.000 claims description 3
- 229940123233 Prostaglandin IP receptor agonist Drugs 0.000 claims description 3
- ZIDQIOZJEJFMOH-JKSUJKDBSA-N (3R,4S)-BW 245C Chemical compound C([C@@H](O)C1CCCCC1)CN1[C@@H](CCCCCCC(O)=O)C(=O)NC1=O ZIDQIOZJEJFMOH-JKSUJKDBSA-N 0.000 claims 2
- KAQKFAOMNZTLHT-OZUDYXHBSA-M prostaglandin I2(1-) Chemical compound O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-M 0.000 claims 2
- WBBLIRPKRKYMTD-SGEDCAFJSA-N 2-[[5-[2-[(z)-[phenyl(pyridin-3-yl)methylidene]amino]oxyethyl]-7,8-dihydronaphthalen-1-yl]oxy]acetic acid Chemical compound C=1CCC=2C(OCC(=O)O)=CC=CC=2C=1CCO\N=C(C=1C=NC=CC=1)\C1=CC=CC=C1 WBBLIRPKRKYMTD-SGEDCAFJSA-N 0.000 claims 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 abstract description 39
- 230000000694 effects Effects 0.000 abstract description 17
- 230000007803 itching Effects 0.000 abstract description 7
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- 230000006399 behavior Effects 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 30
- 238000012360 testing method Methods 0.000 description 24
- 201000004624 Dermatitis Diseases 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 238000001647 drug administration Methods 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 230000002269 spontaneous effect Effects 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 8
- 229960003957 dexamethasone Drugs 0.000 description 8
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 7
- 239000000739 antihistaminic agent Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 102000030621 adenylate cyclase Human genes 0.000 description 6
- 108060000200 adenylate cyclase Proteins 0.000 description 6
- 229960003444 immunosuppressant agent Drugs 0.000 description 6
- 239000003018 immunosuppressive agent Substances 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 229960001967 tacrolimus Drugs 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 108091006335 Prostaglandin I receptors Proteins 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000000043 antiallergic agent Substances 0.000 description 4
- 229940125715 antihistaminic agent Drugs 0.000 description 4
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229960003559 enprostil Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- PTOJVMZPWPAXER-VFJVYMGBSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e,3r)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]hepta-4,5-dienoate Chemical compound O[C@@H]1CC(=O)[C@H](CC=C=CCCC(=O)OC)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 PTOJVMZPWPAXER-VFJVYMGBSA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000033764 rhythmic process Effects 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 description 3
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000000603 Prostaglandin DP receptors Human genes 0.000 description 3
- 102100024448 Prostaglandin E2 receptor EP2 subtype Human genes 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003491 cAMP production Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- KVSPDLWJCJFYEZ-CZQLRZFZSA-N (4-benzamidophenyl) (z)-7-[(1r,2r,3r)-3-hydroxy-2-[(2r)-2-hydroxy-3-phenoxypropoxy]-5-oxocyclopentyl]hept-5-enoate Chemical compound C([C@H]1C(=O)C[C@@H](O)[C@@H]1OC[C@@H](O)COC=1C=CC=CC=1)\C=C/CCCC(=O)OC(C=C1)=CC=C1NC(=O)C1=CC=CC=C1 KVSPDLWJCJFYEZ-CZQLRZFZSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- XMQKDOCUWFCMEJ-JAZPPYFYSA-N 7-[(1r,2s)-2-[4-(1-hydroxyhexyl)phenyl]-5-oxocyclopentyl]heptanoic acid Chemical compound C1=CC(C(O)CCCCC)=CC=C1[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1 XMQKDOCUWFCMEJ-JAZPPYFYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- STJFYCWYHROASW-UHFFFAOYSA-N O-methyl-glaucamine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C2OC(OC)C3=C4OCOC4=CC=C3C12 STJFYCWYHROASW-UHFFFAOYSA-N 0.000 description 2
- 101150053131 PTGER3 gene Proteins 0.000 description 2
- SLDLSMFNGFIPNI-RXYUHBJGSA-N Pimilprost Chemical compound C1[C@@H](CCOCC(=O)OC)C[C@@H]2[C@@H](/C=C/[C@@H](O)C[C@@H](C)CCCC)[C@H](O)C[C@@H]21 SLDLSMFNGFIPNI-RXYUHBJGSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 2
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 2
- 208000036741 Pruritus generalised Diseases 0.000 description 2
- 101150058615 Ptger1 gene Proteins 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010048218 Xeroderma Diseases 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- HITYEEHTEOQBAC-OSIGYOHNSA-N butyl 7-[(4r,5r)-2-butanoyloxy-4-hydroxy-5-[(e,3s)-3-hydroxyoct-1-enyl]cyclopenten-1-yl]heptanoate Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(OC(=O)CCC)=C1CCCCCCC(=O)OCCCC HITYEEHTEOQBAC-OSIGYOHNSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229950001840 pimilprost Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 2
- SPOAFZKFCYREMW-FWYLUGOYSA-N rioprostil Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCCO SPOAFZKFCYREMW-FWYLUGOYSA-N 0.000 description 2
- 229950004712 rioprostil Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LGIPMFCHTFFLFR-PRYZLTTQSA-N 13,14-dehydro-15-cyclohexyl Carbaprostacyclin Chemical compound C([C@@H]1[C@H]2CC(/C[C@H]2C[C@H]1O)=C/CCCC(O)=O)#CC1(O)CCCCC1 LGIPMFCHTFFLFR-PRYZLTTQSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- POFQOMOFTOFTNO-OKZBNKHCSA-N 7-[(1r,2s)-2-[(3s)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoic acid Chemical compound CCCCC[C@H](O)CC[C@H]1CCC(=O)[C@@H]1CCCCCCC(O)=O POFQOMOFTOFTNO-OKZBNKHCSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 101001117517 Homo sapiens Prostaglandin E2 receptor EP3 subtype Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101000883443 Mus musculus Desmoplakin Proteins 0.000 description 1
- 101100029148 Mus musculus Ptger1 gene Proteins 0.000 description 1
- 101100407595 Mus musculus Ptger4 gene Proteins 0.000 description 1
- 101000874159 Mus musculus Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 1
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
- BBRBUTFBTUFFBU-LHACABTQSA-N Ornoprostil Chemical compound CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CC(=O)CCCCC(=O)OC BBRBUTFBTUFFBU-LHACABTQSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100035842 Prostaglandin E2 receptor EP1 subtype Human genes 0.000 description 1
- 102100024447 Prostaglandin E2 receptor EP3 subtype Human genes 0.000 description 1
- 102100024450 Prostaglandin E2 receptor EP4 subtype Human genes 0.000 description 1
- 229940123717 Prostaglandin EP1 receptor agonist Drugs 0.000 description 1
- 229940121820 Prostaglandin EP2 receptor agonist Drugs 0.000 description 1
- 229940122323 Prostaglandin EP3 receptor agonist Drugs 0.000 description 1
- 229940123028 Prostaglandin EP4 receptor agonist Drugs 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 101150109738 Ptger4 gene Proteins 0.000 description 1
- FBQUXLIJKPWCAO-AZIFJQEOSA-N Rivenprost Chemical compound COCC1=CC=CC(C[C@H](O)\C=C\[C@@H]2[C@H](C(=O)C[C@H]2O)CCSCCCC(=O)OC)=C1 FBQUXLIJKPWCAO-AZIFJQEOSA-N 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001275 ca(2+)-mobilization Effects 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960004409 cloprostenol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013078 crystal Chemical group 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229950006865 ecraprost Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000010222 extracellular calcium influx Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- WWSWYXNVCBLWNZ-QIZQQNKQSA-N fluprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(C(F)(F)F)=C1 WWSWYXNVCBLWNZ-QIZQQNKQSA-N 0.000 description 1
- 229950009951 fluprostenol Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960002491 ibudilast Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GNIYHUSSKSFYBD-MFZPGRHISA-N methyl 7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3r)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hepta-4,5-dienoate Chemical compound CCCCC[C@@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=C=CCCC(=O)OC GNIYHUSSKSFYBD-MFZPGRHISA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229950009738 ornoprostil Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229950003837 ozagrel Drugs 0.000 description 1
- SHZKQBHERIJWAO-AATRIKPKSA-N ozagrel Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1CN1C=NC=C1 SHZKQBHERIJWAO-AATRIKPKSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003017 phosphorus Chemical class 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- CIMMACURCPXICP-PNQRDDRVSA-N prostaglandin D1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)[C@@H](O)CC1=O CIMMACURCPXICP-PNQRDDRVSA-N 0.000 description 1
- ANOICLBSJIMQTA-WXGBOJPQSA-N prostaglandin D3 Chemical compound CC\C=C/C[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O ANOICLBSJIMQTA-WXGBOJPQSA-N 0.000 description 1
- CBOMORHDRONZRN-QLOYDKTKSA-N prostaglandin E3 Chemical compound CC\C=C/C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CBOMORHDRONZRN-QLOYDKTKSA-N 0.000 description 1
- 229950005051 prostalene Drugs 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 230000003989 repetitive behavior Effects 0.000 description 1
- 208000013406 repetitive behavior Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- NMAOJFAMEOVURT-RTKIROINSA-N rosaprostol Chemical compound CCCCCC[C@H]1CCC(O)[C@@H]1CCCCCCC(O)=O NMAOJFAMEOVURT-RTKIROINSA-N 0.000 description 1
- 229950003055 rosaprostol Drugs 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Chemical group 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005032 treprostinil Drugs 0.000 description 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229950008081 unoprostone isopropyl Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the present invention relates to a drug for preventing or treating pruritic symptoms (hereinafter, also referred to as an antipruritic), and particularly to an antipruritic agent which is effective in relieving pruritus caused by atopic symptoms.
- an antipruritic a drug for preventing or treating pruritic symptoms
- an antipruritic agent which is effective in relieving pruritus caused by atopic symptoms.
- drugs such as topical steroids, immunosuppressants, antihistamines, and antiallergic drugs have been used for pruritic symptoms.
- steroids and immunosuppressants has been limited due to the side effects of long-term use, and antihistamines and antiallergic drugs have not been sufficiently satisfactory in terms of therapeutic effect.
- antipruritic agents was based on administration of pruritus-inducing substances such as histamine and serotonin into the skin of animals to measure pruritic behavior. It has been reported that the reaction is not due to histamine or the like released from mast cells (J, Dermatologic Science 25, 20-28, 2001).
- An object of the present invention is to provide a drug for preventing or treating pruritic symptoms, particularly a drug for preventing or treating atopic symptoms, based on a new mechanism of action with few side effects.
- the present inventors have established, in order to achieve the above object, an evaluation method described below, and as a result of examining the method using the method, it has been found that prosidan dalandins have an excellent antipruritic effect with few side effects. In particular, they have found that itching can be effectively suppressed due to atopic symptoms, and have completed the present invention.
- a drug for preventing or treating pruritic symptoms comprising a prostaglandin or a pharmaceutically acceptable salt thereof as an active ingredient.
- a medicament for preventing or treating atopic symptoms comprising a glandin or a pharmaceutically acceptable salt thereof as an active ingredient.
- the prostaglandins are prostaglandin agonists.
- the prostaglandin agonist is a prostaglandin DP receptor agonist, a prostaglandin EP receptor agonist, or a prostaglandin IP receptor agonist.
- the above agent wherein the prostaglandins are prostaglandins E.
- the prostaglandins are BW2450C, ZK110841, RS93350,15-methyl PGD2 or an optical isomer and prostaglandin.
- the above-mentioned drug which is one or more selected from the group consisting of gin D2.
- the prostaglandins are prostaglandins D2, BW2450C, ZK110841, RS93350 and 15-methyl PGD. 2.
- the above-mentioned drug which is one or more selected from the group consisting of 2.
- the prostaglandins are prostaglandin E2, enprostil, sulprostone, AH13205, GR63799, M & B 28767, misoprostol, 11-doxy-PGE1, ONO-AE-248,
- the above agent which is one or more members selected from the group consisting of TEI 3356, 16,16-dimethyl-PGE2, 1-hydroxy-PGE1, prostaglandin E1, and limaprost.
- the above-mentioned drug wherein the prostaglandins are one or more selected from the group consisting of prostaglandin E 1, prostaglandin E 2, sulprostone, enprostil and limaprost. provide.
- the prostaglandin E is one or more selected from prostaglandin E1, prostaglandin E2 and limaprost.
- the prostaglandins are one or more members selected from the group consisting of cicaprost, beraprost, iloprost, NO_1301, cyclapine, cyclaline, prostaglandin I2 and clinprost.
- the above-mentioned drug is provided.
- the above drug wherein the prostaglandins are one or more selected from the group consisting of prostaglandin I 2, cicaprost, beraprost, iloprost, and clinprost.
- the above drug wherein the atopic symptom is atopic dermatitis or atopic conjunctivitis.
- the above drug which is an external preparation.
- a method for preventing or treating a pruritic condition comprising administering to a mammal an amount of prostaglandins or a pharmaceutically acceptable salt thereof effective for preventing or treating the condition.
- I will provide a.
- an amount of prosthesis is effective to prevent or treat the condition.
- a method for preventing or treating atopic symptoms which comprises administering a compound or a pharmaceutically acceptable salt thereof to a mammal.
- a prostaglandin or a pharmaceutically acceptable salt thereof in the manufacture of a prophylactic or therapeutic agent for pruritic symptoms.
- a prostaglandin or a pharmaceutically acceptable salt thereof in the manufacture of a prophylactic or therapeutic agent for atopic symptoms.
- FIG. 1 shows dermatitis scores observed over time for 4 weeks after drug administration.
- FIG. 2 shows the dermatitis score observed 4 weeks after drug administration.
- the present invention is characterized by containing prostaglandins or a pharmaceutically acceptable salt thereof.
- prostaglandins or pharmaceutically acceptable salts thereof further includes all isomers (geometric isomers, optical isomers), hydrates, solvates, and crystal forms. Include.
- “pharmaceutically acceptable salts” include, for example, salts with alkali metals such as sodium and potassium, salts with alkaline earth metals such as calcium and magnesium, ammonia, methylamine, dimethylamine, and cyclopentylamine , Benzylamine, piperidine, monoethanolamine, diethanolamine, monomethylmonoethanolamine, tromethamine, lysine, tetraalkylammonium, salts with tris (hydroxymethyl) aminomethane, sulfuric acid, hydrochloric acid, phosphorus Salts with mineral acids such as acids, and salts with organic acids such as acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, methyl sulfonic acid, and benzene sulfonic acid.
- alkali metals such as sodium and potassium
- alkaline earth metals such as calcium and magnesium
- ammonia methylamine, dimethylamine, and cyclopentylamine
- prostaglandins which are the active ingredients of the present invention, have a basic structure of prostanoic acid, and are classified into A, B, C, D, and E according to the difference between the oxygen atom attached to the five-membered ring portion and the double bond. , F, G, H, I, J groups, depending on the number of double bonds in the side chain, 1, 2, 3 They are further classified into groups. Prostaglandins may be of natural or synthetic origin.
- prostaglandin Ds refer to prostanoic acid having a 9 ⁇ -hydroxyl group and an 11-oxo group.
- prostaglandins are prostanoic acids having a 9-oxo group and a 11-hydroxyl group.
- the prostaglandins I are prostanoic acids in a bicyclo ring having an 11-hydroxyl group and a 6,9-epoxy group.
- Preferred prostaglandins are prostaglandin agonists.
- Prostaglandin agonist means a substance that acts operatively on a prostaglandin receptor. If so, it is included in the prostaglandin agonist of the present invention.
- prostaglandin receptor is a receptor specific to each prostaglandin, and is coupled to G protein to form cyclic AMP diinositol 1,4,5-trisphosphate Is a second messenger and is linked to a signaling system.
- prostaglandin agonists are prostaglandin DP receptor, EP receptor or IP receptor agonists.
- Prostaglandin DP receptor agonist showed affinity for DP receptor in a binding test using mouse DP receptor-expressing cells, and activated adenylate cyclase system to increase cAMP production. Can be determined to be dependently increased (Proc Natl Acad Sci US A. 1994 Nov 8; 91 (23): 11192-6; the contents of this document are incorporated herein by reference).
- Prostaglandin EP receptor agonists can be classified into four subtype receptor agonists, EP1, EP2, EP3, and EP4, depending on the type of receptor.
- EP 1 receptor is a receptor that couples to the Ca 2+ mobilization system
- EP 2 E
- the P4 receptor is a receptor coupled to the activation of adenylate cyclase
- the EP3 receptor is a receptor coupled to the inhibition of adenylate cyclase.
- the prostaglandin EP1 receptor agonist showed affinity for the EP1 receptor in a binding test using mouse EP1 receptor expression cells, and was caused by extracellular Ca 2+ influx in the same cells. It can be determined that an increase in intracellular [Ca 2+ ] is caused depending on the concentration of the compound (J Biol Chem 1993 Sep 25; 26 ⁇ (27): 2017 5-8, Biochim Biophys Acta 1995 May 11) 1244 (1): 41-8; the contents of these references are incorporated herein by reference).
- the prostaglandin EP2 receptor agonist showed affinity for the EP2 receptor in a binding test using mouse EP2 receptor-expressing cells, and showed the adenylate cyclase system in the cells. It can be determined that activation and cAMP production increase in a compound-dependent manner (Br J Pharmacol 1986 Jan; 87 (l): 45-56, Mol Pharmacol 1994 Aug; 46 (2): 213-20 See, the contents of these documents are hereby incorporated by reference).
- the prostaglandin EP3 receptor agonist is classified into j8 or ⁇ , depending on the type of the receptor, and the EP3 receptor agonist was tested in a binding test using mouse EP3 ⁇ receptor-expressing cells. It can be determined that the affinity for the receptor is observed, and that the activation of the adenylate cyclase system is suppressed in the same cell and the production of cAMP is reduced in a concentration-dependent manner of the compound.
- the prostaglandin IP receptor agonist showed affinity for the IP receptor in a binding test using mouse IP receptor-expressing cells, and activated the adenylate cyclase system in the same cells. It can be determined that the production increases depending on the concentration of the conjugate. Alternatively, it can be determined that an increase in PI (phosphatidylinositol) metabolism in the same cell is caused depending on the concentration of the compound (J Biol Chem 1994 Apr 1; 269 (13): 9986-92, FEBS Lett 1994 May 9). ; 344 (1): 74-8; the contents of these references are incorporated herein by reference).
- prostaglandin DP include prostaglandin El, prostaglandin E2, prostaglandin E3, ecraprost, clinprost, and pimilprost.
- Pimilprost includes Limaprost, Ozagrel, Ibudilast, Ornoprostil, Alprostadil, Enprostil, Prostaglandin 12, Prostaglandin Glandin 13, Berapros B, Iloprost, BW245 C, ZK110841, RS 93 520, Sulprostone, AH 13205, GR 63799, M & B 28767, Fluprostenol, Cloprostenol ), Prosule Yuen (Prostalene), Sika Pro (Cicaprost), Octimibata (Octimibata), Misoprostol (Misoprostol), Rioprostil (Rioprostil), Epoprostenol (Epoprostenol), Dinoprostone (
- Representative DP receptor agonists include BW245 C, ZK110841, RS93520, 15-methyl PGD 2 and its optical isomers (particularly, 15 (S) -1 15-methyl-PGD 2), and prostaglandin D 2.
- BW245 C ZK110841, RS93520, 15-methyl PGD 2 and its optical isomers (particularly, 15 (S) -1 15-methyl-PGD 2), and prostaglandin D 2.
- EP receptor agonists include prostaglandin E2, enprostil, sulprostone, AH13205, GR63799, M & B28767, misoprostol, 11-dexoxy-PGE1, ONO-AE-248, TE13356, 16,16-Dimethyl-PGE2, 1-hydroxy-PGE1, prostaglandin E1, and limaprost.
- IP receptor agonists include cicaprost, beraprost, iloprost, ⁇ NO-1301, levulina cyclin, prostaglandin 12, and clinprost.
- BW245 C 3-[(3R) -3-cyclohexyl-3-hydroxypropyl] -2,5-dioxo- (4S) -imidazolidinehepnoic acid
- ZK110841 7-[(121,311,510-5-chloro-2-[(, 33) -3-cyclohexyl-3-hydroxy-1-propenyl] -3-hydroxycyclopentyl]-(5Z )-5-hepte Acid
- ONO-8815 L-Lysine (Z) —7-[(1R, 2R, 3R, 5R) -5-chloro-2-3-hydroxy-2 [(E)-(S) -4- (ethylethyl mouth) -4-hydroxy-1-butenyl] cyclopentyl] -5-heptenoate
- the antipruritic agent of the present invention is not particularly limited as long as it reduces or eliminates pruritus, and is particularly effective for itching due to atopy (antigen-specific immune reaction mediated by IgE antibody). From this point, the antipruritic agent of the present invention includes a drug for preventing or treating atopic symptoms.
- the “pruritic condition” refers to a condition having localized or generalized itching and inflammation related thereto on the skin and mucous membranes.
- scabies measles, eczema, xeroderma (xeroderma senile, sebum deficient eczema, etc.), psoriasis, pruritus cutis, prurigo.
- atopic symptom refers to a symptom having localized or generalized itching caused by atopy and inflammation associated therewith on the skin and mucous membranes, that is, a pruritic symptom caused by atopy.
- examples include atopic dermatitis and atopic conjunctivitis.
- atopic dermatitis refers to a disease in which pruritus eczema is the main lesion that repeats exacerbation and remission, and occurs in individuals with an atopic predisposition (a predisposition to produce IgE antibodies). It's easy to do.
- This evaluation method focuses on the longer duration of the pruritic behavior of NC / Nga mice that developed atopic dermatitis compared with that of mice of other strains.
- this evaluation method is characterized by extracting and measuring spontaneous pruritic behavior of NC / Nga mice that have developed atopic dermatitis for a certain period of time or more. This is a method for evaluating a drug having an effect.
- the NC / Nga mouse used for the evaluation method is known as a diseased mouse with atopic dermatitis. These mice spontaneously cause severe pruritic behavior and skin lesions, and exhibit symptoms similar to atopic dermatitis, such as marked infiltration of inflammatory cells into the lesions and an increase in blood IgE levels (H. Matsuda, et al., Int Immunol. 9 (3), 461-466 (1997); H. Suto, et al., Int Arch Allergy Immunol. 120 (suppl 1), 70-75 (1999). ).
- the NC / Nga mouse is not particularly limited as long as it develops atopic dermatitis, but is preferably a mouse of about 8 weeks of age or older, particularly preferably a mouse of 15 to 20 weeks of age. is there.
- test drug and the control drug can be administered orally, by application, intradermally, intraperitoneally, etc., and preferably by application.
- the pruritus behavior is measured by a device that detects the repetitive behavior of the animal.
- a device for detecting a repetitive operation is specifically described below.
- the NC / Nga mouse with atopic dermatitis has magnets on both hind limbs, and the mouse is housed in a space around which a coil is wound. When the mouse behaves, the magnet moves with it, and a current is generated in the coil. And by the movement of the magnet, A change in current occurs, which is detected, measured and analyzed.
- This device is commercially available as a pruritus measurement system (manufactured by Neuroscience).
- the detected pruritic behavior is classified by the length of pruritus time, the frequency is tabulated, and statistical analysis is performed. Extract itching time of 1.0 second or more. More preferably, extract those for 1.5 seconds or more. 1. If you extract more than 5 seconds, the error will be smaller.
- This evaluation method has made it possible to evaluate drugs having an antipruritic effect on atopic dermatitis at a high level of accuracy.
- movements other than pruritic behaviour such as walking, which causes errors
- pruritic behaviour which is a general symptom that animals naturally undergo
- the experimental animals were male NC / Nga mice (14 weeks old) with atopic dermatitis-like symptoms, ICR mice (7 weeks old), BALB / c mice (5 weeks old) as control groups, NC / Nga mice (8 weeks old) that did not develop dermatitis and dermatitis were used, each having a body weight of about 30 g.
- a scratch measuring magnet was inserted into the hind leg of the above animal, and the test was performed one day later.
- Each experimental animal was placed in a measurement cage one by one, and after acclimation for 1 hour, the pruritus behavior was measured by a 24-hour pruritus measurement system (manufactured by Nichiguchi Science Co., Ltd.).
- the recorded waveform was measured using software for scratch measurement and analysis (NeuroSciences Inc.) for 0.3 to 0.5 seconds, 0.5 to 1.0 seconds, 1.0 to 1.5 seconds, and 1.5 seconds.
- the movement of the foot for more than a second was quantified as one pruritic behavior, statistical analysis was performed, and a significant difference test between mouse strains was performed.
- ICR ICR, BALB / c, dermatitis onset and non-onset Number of spontaneous pruritus in NC / Nga mice Duration (sec) ICR BALB / c NC / Nga (not onset) NC / Nga (onset)
- the antipruritic effect according to the above-established evaluation method was examined using a drug whose antipruritic effect was already known.
- mice 14 male NC / Nga male mice with a body weight of about 30 g and developing atopic dermatitis, 6 mice per group.
- Prostaglandins inhibited pruritic behavior for which conventional antihistamines and antiallergic drugs were not effective. Therefore, it is considered that prostaglandins suppress pruritus caused by a different mechanism of action from these drugs.
- prostaglandins have an antipruritic effect equal to or higher than that of steroids and immunosuppressants whose long-term use is restricted by side effects when applied topically. Therefore, prostaglandins are superior to these drugs in that they have few side effects due to topical application and can be used for a long period of time.
- the antipruritic agent of the present invention can be administered by any of oral, parenteral or topical routes.
- the appropriate amount can be adjusted as appropriate according to the patient's weight, age, sex, etc., but is usually 0.1 to L: 0 g per administration, and can be administered once to several times a day.
- the antipruritic agent of the present invention can also be used in combination with an antihistamine (eg, diphenhydramine, carbinoxamine, chlorpheniramine, ranitidine, a salt thereof, etc.) as an active ingredient.
- an antihistamine eg, diphenhydramine, carbinoxamine, chlorpheniramine, ranitidine, a salt thereof, etc.
- the antipruritic agent of the present invention can be prepared as a pharmaceutical composition using carriers, excipients, and other additives commonly used in the preparation of active ingredients.
- Pharmaceutical carriers and excipients include, for example, water, ethanol, lactose, microcrystalline cellulose, liquid paraffin, hydrogenated oil, honey, squalane, stearyl alcohol, ethylene glycol, and other commonly used substances. Can be given.
- additives examples include disintegrants (starch, etc.), binders ⁇ hydroxypropylcellulose, low-substituted hydroxypropylcellulose ⁇ , lubricants (talc, glyceryl stearate, etc.), antioxidants, preservatives (paraben, etc.). ), Coating agents (gelatin, hydroxypropyl cell mouth, etc.), coloring agents, flavoring agents, whitening agents (sodium ellagate, etc.), surfactants (sorbitan fatty acid esters, etc.), plasticizers, Examples of commonly used ingredients such as humectants (glycerin, propylene glycol, polyethylene dalicol, hyaluronic acid, etc.) are included.
- humectants glycerin, propylene glycol, polyethylene dalicol, hyaluronic acid, etc.
- the antipruritic agent of the present invention is in the form of tablets, granules, powders, capsules, solutions, gels, plasters, ointments, creams, patches, aerosols, etc. It can be administered as an agent (including eye drops and nasal drops).
- Preferred dosage forms include external preparations because they can be directly administered to the affected area, are easy to administer, and reduce the possibility of systemic side effects.
- the “external preparation” includes a liquid preparation for external use, an aerosol, a powder for external use, an ointment, a cream, a gel, a plaster, a patch and the like.
- the following components were mixed and uniformly emulsified, and a perfume was added in an appropriate amount to obtain 500 g of a cream.
- the resulting mixed powder was filled into No. 2 hard capsules in a quantity of 250 mg to obtain capsules.
- the following components were mixed and uniformly emulsified, and a perfume was added in an appropriate amount to obtain 500 g of a cream.
- Test example 1 Effect on spontaneous pruritus behavior in NC mice
- Magnets are implanted in both feet of a 20-week-old atopic dermatitis-causing NC / Nga mouse (purchased by SLC), weighing about 30 g, and the movement of the feet is sensed using the magnetic force to detect the pruritus measurement system (Neuroscience). ). Of the pulling actions, those with a duration of 1.5 seconds or more were regarded as pruritic actions, and the number of times was continuously measured. Since the pruritic behavior has a diurnal rhythm, after measuring the diurnal pruritic rhythm of each animal for 24 hours from the day before the test, 0.1% prostaglandin E 2 (PGE2) dissolved in 100% ethanol (Cayman Ch.
- PGE2 prostaglandin E 2
- Prostaglandin E2 when applied topically at 0.1%, reduced spontaneous pruritus in NC mice with a similar effect as dexamethasone and tacrolimus, which are known to have antipruritic effects.
- Test Example 2 Effect on NC mouse spontaneous pruritus
- those with a duration of 1.5 seconds or more were regarded as pruritic behavior, and the number of times was continuously measured. Since the pruritic behavior has a daily rhythm, the daily pruritic rhythm of each animal was measured 24 hours from the day before the test, and then each drug dissolved in 100% ethanol was applied to the back skin at a rate of 0.2 ml / mouse.
- Prostaglandin E2 (PGE2) (Cayman Chemical), prostaglandin D2 (PGD2) (Cayman Chemical), limaprost (synthetic product), sulprostone (synthetic product) and beraprost (synthetic product) as the drug of the present invention was. Then, the pruritic behavior at 24 hours was measured, and the number of pruritic behavior before and after drug administration was compared. For the experimental data, the pruritus suppression rate was calculated from the total number of pruritus 24 hours before and after drug application, and is shown in Table 2.
- Pruritus suppression rate (%) (pruritic frequency before application / pruritic frequency after application) xlOOZ pruritic frequency before application
- Significant difference test is a paired t-test for the number of pruritus before and after drug application in individual animals of each drug concentration application group (paired t-test). 0.5% or less
- Prostaglandin E 2 reduced spontaneous pruritic behavior in NC mice by a topical application of 0.1% with a similar effect to that of dexamethasone and evening chlorimus, which are known drugs for treating atopic dermatitis.
- Prostaglandin D2, limaprost, sulprostone and beraprost are also known as these conventional atopic skins.
- Test Example 3 Effect on NC mouse skin inflammation model
- mice After living together for 2 weeks, the purchased mice were taken out and reared in separate cages for 8 mice per cage for another 14 weeks until the start of the test. (4) Immediately before the start of application, the mice were sorted so that the flame scorers in each cage became equal, and the mice were bred with four animals per cage.
- Flame score was scored as asymptomatic: 0, mild: 1, moderate: 2, severe: 3 for four items: fur, alopecia, bleeding, and crust formation (minimum total: 0, maximum total) : 12).
- Drug administration 100% ethanol on the back skin of 20-week-old NC mice with skin inflammation caused by living with NC mice with skin inflammation, 0.01% each of limaprost and beraprost dissolved in 100% ethanol (each synthetic product) ) Were applied 200 times each for 7 times / week for 4 weeks using an Eppendorf pipette.
- the untreated group received no treatment.
- Each group was tested with 8 animals per group, and the skin irritations were observed once / week for 4 weeks using the above dermatitis score.
- the mean ⁇ standard difference was determined from the flame score of each group, and the significant difference between each drug administration group and the ethanol administration group was statistically processed using a t-test (t-test).
- FIGS. 1 and 2 The results of observation of skin irritations are shown in FIGS. 1 and 2 (*, P: 0.05). As is clear from FIGS. 1 and 2, the limaprost and beraprost administration groups showed a significant dermatitis scoring inhibitory effect as compared with the ethanol administration group. Industrial applicability
- the antipruritic agent of the present invention can specifically suppress itching that causes inflammation such as dermatitis for pruritic symptoms, and is particularly effective for atopic symptoms.
- the antipruritic agent of the present invention has excellent antipruritic effect without side effects as seen in conventional steroids and immunosuppressants, and is therefore highly safe even if used long-term. Further, the antipruritic agent of the present invention can suppress itching that is not effective with conventional antihistamines and antiallergic agents.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA04003851A MXPA04003851A (es) | 2002-02-22 | 2003-02-21 | Antipruriticos. |
JP2003569208A JPWO2003070252A1 (ja) | 2002-02-22 | 2003-02-21 | 止痒剤 |
US10/492,948 US20040266880A1 (en) | 2002-02-22 | 2003-02-21 | Antipruritics |
KR10-2004-7008151A KR20040083416A (ko) | 2002-02-22 | 2003-02-21 | 지양제 |
CA002463438A CA2463438A1 (en) | 2002-02-22 | 2003-02-21 | Antipruritics |
EP03703357A EP1477170A4 (en) | 2002-02-22 | 2003-02-21 | ANTIPRURIGINOUS AGENTS |
AU2003207102A AU2003207102C1 (en) | 2002-02-22 | 2003-02-21 | Antipruritics |
NO20041579A NO20041579L (no) | 2002-02-22 | 2004-04-19 | Klostillende midler |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002/46301 | 2002-02-22 | ||
JP2002046301 | 2002-02-22 | ||
JP2002226680 | 2002-08-02 | ||
JP2002/226680 | 2002-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003070252A1 true WO2003070252A1 (fr) | 2003-08-28 |
Family
ID=27759681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/001920 WO2003070252A1 (fr) | 2002-02-22 | 2003-02-21 | Agents antiprurigineux |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1477170A4 (ja) |
JP (1) | JPWO2003070252A1 (ja) |
KR (1) | KR20040083416A (ja) |
CN (1) | CN1610552A (ja) |
AU (1) | AU2003207102C1 (ja) |
CA (1) | CA2463438A1 (ja) |
MX (1) | MXPA04003851A (ja) |
NO (1) | NO20041579L (ja) |
PL (1) | PL369936A1 (ja) |
WO (1) | WO2003070252A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014394A1 (ja) * | 2002-08-09 | 2004-02-19 | Taisho Pharmaceutical Co.,Ltd. | 止痒剤 |
WO2004043471A1 (ja) * | 2002-11-13 | 2004-05-27 | Taisho Pharmaceutical Co., Ltd. | 鎮痒剤 |
JP2005247843A (ja) * | 2004-02-06 | 2005-09-15 | Taisho Pharmaceut Co Ltd | 掻痒治療剤 |
JP2005247842A (ja) * | 2004-02-06 | 2005-09-15 | Taisho Pharmaceut Co Ltd | 乾皮症治療剤 |
US7737182B2 (en) | 2002-08-09 | 2010-06-15 | Taisho Pharmaceutical Co., Ltd. | Pharmaceuticals for xerosis |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060128810A1 (en) * | 2002-10-10 | 2006-06-15 | Kyoto University | Remedies for allergic diseases |
US20060188499A1 (en) | 2005-02-14 | 2006-08-24 | Leung Donald Y | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
ITCE20070007A1 (it) * | 2007-04-02 | 2008-10-03 | Mario Immacolato Paternuosto | Nuova indicazione per l'uso orale del misoprostolo nel trattamento del prurito quale sintomo di patologie non dermatologiche primitive e per l'uso topico delle ustioni |
KR101432244B1 (ko) * | 2011-04-27 | 2014-08-27 | 영진약품공업 주식회사 | 안정성이 개선된 리마프로스트 함유 약제학적 조성물 및 이의 제조방법 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998027971A1 (en) * | 1996-12-23 | 1998-07-02 | Michael Albert Kamm | Pharmaceutical composition for treating fecal incontinence and anal itch |
WO1999062555A1 (fr) * | 1998-06-03 | 1999-12-09 | Shionogi & Co., Ltd. | Remedes contre le prurit renfermant des antagonistes vis-a-vis de pgd¿2? |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252602A (en) * | 1991-10-11 | 1993-10-12 | Rafeul Alam | Effects of misoprostol on allergic responses |
WO2002045718A1 (en) * | 2000-12-08 | 2002-06-13 | Institut Pasteur De Lille | Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells |
-
2003
- 2003-02-21 KR KR10-2004-7008151A patent/KR20040083416A/ko not_active Application Discontinuation
- 2003-02-21 WO PCT/JP2003/001920 patent/WO2003070252A1/ja active Application Filing
- 2003-02-21 CA CA002463438A patent/CA2463438A1/en not_active Abandoned
- 2003-02-21 CN CNA038018268A patent/CN1610552A/zh active Pending
- 2003-02-21 MX MXPA04003851A patent/MXPA04003851A/es unknown
- 2003-02-21 JP JP2003569208A patent/JPWO2003070252A1/ja active Pending
- 2003-02-21 AU AU2003207102A patent/AU2003207102C1/en not_active Ceased
- 2003-02-21 PL PL03369936A patent/PL369936A1/xx not_active Application Discontinuation
- 2003-02-21 EP EP03703357A patent/EP1477170A4/en not_active Withdrawn
-
2004
- 2004-04-19 NO NO20041579A patent/NO20041579L/no not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998027971A1 (en) * | 1996-12-23 | 1998-07-02 | Michael Albert Kamm | Pharmaceutical composition for treating fecal incontinence and anal itch |
WO1999062555A1 (fr) * | 1998-06-03 | 1999-12-09 | Shionogi & Co., Ltd. | Remedes contre le prurit renfermant des antagonistes vis-a-vis de pgd¿2? |
Non-Patent Citations (1)
Title |
---|
See also references of EP1477170A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014394A1 (ja) * | 2002-08-09 | 2004-02-19 | Taisho Pharmaceutical Co.,Ltd. | 止痒剤 |
US7718701B2 (en) | 2002-08-09 | 2010-05-18 | Taisho Pharmaceutical Co., Ltd. | Antipruritic agent |
US7737182B2 (en) | 2002-08-09 | 2010-06-15 | Taisho Pharmaceutical Co., Ltd. | Pharmaceuticals for xerosis |
WO2004043471A1 (ja) * | 2002-11-13 | 2004-05-27 | Taisho Pharmaceutical Co., Ltd. | 鎮痒剤 |
JP2005247843A (ja) * | 2004-02-06 | 2005-09-15 | Taisho Pharmaceut Co Ltd | 掻痒治療剤 |
JP2005247842A (ja) * | 2004-02-06 | 2005-09-15 | Taisho Pharmaceut Co Ltd | 乾皮症治療剤 |
Also Published As
Publication number | Publication date |
---|---|
KR20040083416A (ko) | 2004-10-01 |
EP1477170A1 (en) | 2004-11-17 |
PL369936A1 (en) | 2005-05-02 |
NO20041579L (no) | 2004-05-18 |
EP1477170A4 (en) | 2007-09-05 |
CA2463438A1 (en) | 2003-08-28 |
CN1610552A (zh) | 2005-04-27 |
MXPA04003851A (es) | 2004-07-08 |
NO20041579D0 (no) | 2004-04-19 |
AU2003207102B2 (en) | 2007-12-13 |
AU2003207102A1 (en) | 2003-09-09 |
JPWO2003070252A1 (ja) | 2005-06-09 |
AU2003207102C1 (en) | 2008-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10695308B2 (en) | Inhalation formulations of treprostinil | |
US9901568B2 (en) | Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound | |
EP1807083B1 (en) | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis | |
US20140275237A1 (en) | Beraprost isomer as an agent for the treatment of viral infection | |
EP1871380B1 (en) | Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders | |
RU2324484C2 (ru) | Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты) | |
KR20010032000A (ko) | 레티노이드 길항제를 이용한 티-보조 세포 제2형 중재면역 질환의 치료 | |
JP6408426B2 (ja) | 胃腸障害処置用プロスタグランジン誘導体 | |
JP2012131829A (ja) | そう痒状態の処置のためのmglur5アンタゴニストの使用 | |
WO2003070252A1 (fr) | Agents antiprurigineux | |
US20040266880A1 (en) | Antipruritics | |
EP1563845A1 (en) | Remedies for allergic diseases | |
JP5382898B2 (ja) | 乾皮症治療剤 | |
TWI286932B (en) | Pharmaceutical composition for eliminating or reducing potential iridic pigmentation | |
JP2004533443A (ja) | 治療的方法 | |
IE59338B1 (en) | Prostacyclins, their analogues or prostaglandins and thromboxane antagonists for the treatment of thrombotic and thrombo-embolic syndromes | |
TW200848059A (en) | Composition for protecting mitochondria | |
JP2023184678A (ja) | 皮膚線維症を処置するための組成物および方法 | |
JPS61172820A (ja) | カルシウム拮抗剤 | |
JP4477504B2 (ja) | 鎮痒剤 | |
US20020115661A1 (en) | Method for treating chronic obstructive pulmonary disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003569208 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2463438 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10492948 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003207102 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/003851 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003703357 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047008151 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038018268 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003703357 Country of ref document: EP |